The Progress of Therapeutic Vaccination with Regard to Tuberculosis by Pere-Joan Cardona
REVIEW
published: 28 September 2016
doi: 10.3389/fmicb.2016.01536
Frontiers in Microbiology | www.frontiersin.org 1 September 2016 | Volume 7 | Article 1536
Edited by:
Thomas Dandekar,
University of Würzburg, Germany
Reviewed by:
Tianyu Zhang,
Guangzhou Institutes of Biomedicine
and Health (CAS), China
Hiroki Iwai,






This article was submitted to
Infectious Diseases,
a section of the journal
Frontiers in Microbiology
Received: 28 July 2016
Accepted: 13 September 2016
Published: 28 September 2016
Citation:
Cardona P-J (2016) The Progress of




The Progress of Therapeutic
Vaccination with Regard to
Tuberculosis
Pere-Joan Cardona*
Unitat de Tuberculosi Experimental, Universitat Autònoma de Barcelona, CIBERES, Fundació Institut Germans Trias i Pujol,
Badalona, Spain
A major problem with tuberculosis (TB) control is the long duration of drug therapy–both
for latent and for active TB. Therapeutic vaccination has been postulated to improve
this situation, and to this end there are several candidates already in clinical phases
of development. These candidates follow two main designs, namely bacilli-directed
therapy based on inactivated -whole or -fragmented bacillus (Mycobacterium w and
RUTI) or fusion proteins that integrate non-replicating bacilli -related antigens (H56
vaccine), and host-directed therapy to reduce the tissue destruction. The administration
of inactivated Mycobacterium vaccae prevents the “Koch phenomenon” response,
and oral administration of heat-killed Mycobacterium manresensis prevents excessive
neutrophilic infiltration of the lesions. This review also tries to explain the success of
Mycobacterium tuberculosis by reviewing its evolution from infection to disease, and
highlights the lack of a definitive understanding of the natural history of TB pathology
and the need to improve our knowledge on TB immunology and pathogenesis.
Keywords: Mycobacterium tuberculosis, vaccines, Mycobacterium w, Mycobacterium indicus pranii,
Mycobacterium vaccae, Mycobacterium manresensis, H56, neutrophils
INTRODUCTION: UNDERSTANDING TB INDUCTION
Tuberculosis (TB) is still a major threat for humankind and is by far the most successful disease
caused by an infectious agent ever. Indeed, it has been calculated that TB has already caused
1,000,000,000 deaths over the last 200 years alone (Paulson, 2013). Furthermore, TB is a condition
highly affected by stigma. Shame and blame keep affected individual patients and society as a whole
from putting TB high on the political and scientific agenda (Chang and Cataldo, 2014). TB still
causes 1.5 million deaths and 10 million new cases per year (World Health Organization, 2015).
In fact, it is calculated that a third of humankind already has a latent tuberculosis infection (LTBI;
Dye et al., 1999; Dheda et al., 2015). After exposure to an active case of TB–especially, intensive and
durable exposure to a highly infectious index case with cavitary TB and poor cough etiquette- LTBI
may ensue; and of those individuals subsequently latently infected, around 10% will develop overt
TB in subsequent years. Young individuals and those with reduced protective immunity stand the
highest chance of developing TB following exposure; pregnant women, those with HIV coinfection,
but to a leser degree also those with diabetes, etc. (Trauer et al., 2016). Furthermore, LTBI can last
for a lengthy period, although the exact period remains a matter of controversy. Some authors,
for example, have claimed that “once infected always infected” based on the “unitary concept”
developed by Stead in 1967 (Stead, 1967; Cardona, 2015). Others, in contrast, reduce the magnitude
of the infection to a limited, although relatively long, period of time, i.e., around 10 years (Cardona
and Ruiz-Manzano, 2004).
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Non-replicating (NR) bacilli are the responsible for this
phenomenon as they arise due to the environmental stress caused
by the immune response or chemotherapy itself (Wayne and
Sohaskey, 2001). This stress causes a drastic change in the
metabolism of the bacilli to become NR, a fact that makes
them less vulnerable to chemotherapy or immune responses
(Baer et al., 2015). As such, NR-Mycobacterium tuberculosis (NR-
Mtb) are directly responsible for the extraordinary length of the
chemotherapy against latent and active TB (Mitchison, 1965).
Therapeutic vaccines appear in this scenario where there is
an urgent need for a new tool to shorten the chemotherapy
treatment.
The Host Scenario: Alveoli Are Designed
for Gas Exchange
It is not the aim of this article to extensively review the natural
history of TB. However, it is very important to provide an
overview of this disease in order to understand the battlefield on
which infection takes place. In the case of M. tuberculosis (Mtb),
this is especially important, as it targets one of the weakest links
in the human immune system, namely the alveolar macrophage
(AM).
Contrary to the normal, somewhat anthropocentric-type view,
the AM is not some sort of police officer constantly on the look-
out for pathogens and ready to deliver its antigens to trigger a
fast and strong immune response. Alveoli are designed for gas
exchange and have a very delicate structure, which is why we
should perhaps consider the AM to be a highly specialized cleaner
thatmust keep the space assigned to it clean (Figure 1). Following
this anthropocentric approach, we can imagine this cleaner in a
25 m2 room, the door of which opens every 6 s to allow the entry
of external air along with large quantities of dust and pathogens.
Figure 1 illustrates this by showing the lung as a large city,
such as Barcelona (Catalonia), filled with 250 million 25 m2
rooms. This illustrates roughly the low range of the alveoli
number in adults (Ochs et al., 2004) and, consequently, the same
number of AMs, themost abundant antigen-presenting cell in the
alveolar spaces (Guth et al., 2009), as it is logical to infer that each
alveolus is occupied by a single AM (Suarez et al., 2012; Peake and
Pinkerton, 2015). In this scenario, of healthy lung parenchyma,
the presence, and role of dendritic cells (DCs) in the alveoli is
very limited, if any, as they are present in very low numbers in the
parenchyma as a whole (around 2%) and thus essentially absent
in the healthy alveolar space.Moreover, even if present, AMs tend
to suppress their activity (Landsman and Jung, 2007; Linton and
Thoman, 2014). Consequently, there is a very particular scenario
in which the conductor (the AM) is very reluctant to trigger any
inflammatory response. This results in a two important delays
in immunological surveillance, namely in communication level
with the lymph node for the antigenic presentation; and in the
attraction of specific lymphocytes that are able to activate the
infected AMs.
The alveoli have another important characteristics, namely
that they are mobile as they must be inflated and deflated in order
to allow the entry of air (Macklem, 2005). This is possible because
of the presence of a surfactant, produced by type II pneumocytes,
which provides the surface tension required to avoid the collapse
of the alveolus, which has a diameter of around 300 µm. At the
same time alveoli must be sealed to ensure a lack of contact with
the plasma transuded from the capillary network as this would
constantly vary the surface tension (Suarez et al., 2012). This
means that no antibodies can reach the alveoli, even when there is
a minimal space between the capillary and the alveoli in order to
allow gas transfer (Figure 2). Fortunately, the surfactant also has
a micobactericidal activity (Arcos et al., 2011) and can contribute
to the defense, along with some activity of AMs themselves, as
a result of the phagocytosis of previously cleaned particles (that
can also be detrimental) or a protective genetic background (Abel
et al., 2014).
Overall, this means that in the context of a single AM
infection, specific lymphocytes are not attracted, and that specific
antibodies cannot reach the alveoli, unless a strong inflammatory
response is triggered to disturb this equilibrium. This is the
perfect scenario forMtb infection and therefore makes the design
of a prophylactic vaccine rather difficult, as has been noted
recently (Lalvani et al., 2013; Kaufmann et al., 2015).
Latent Tuberculosis Infection (LTBI):
Triggering the Immune Response
Figure 3 shows the interaction between Mtb and the immune
response in the scenario described above. This interaction defines
a cycle in which a fine balance is established between the host
and Mtb. The bacilli initially grow in the AM. This growth is
very slow (every 24 h) and may therefore delay the induction of
danger signals from the AM (Kimura et al., 2014). Depending
on the strain, Mtb has a greater or lesser ability to avoid
apoptosis of the infected AM, a process that could arrest the
inflammatory response and limit bacillary growth (Lee et al.,
2006). Indeed, a necrotic AM favors supplemental growth of the
bacilli, thus increasing the bacillary load for the new incoming or
for the neighboring AMs. An efficacious inflammatory response
is triggered once sufficient AMs have been infected, thus allowing
the entry of PMNs and monocytes from the capillary that start to
build a granulomatous lesion. As a result of this bypass, the seal
of the alveoli is broken and the bacilli can reach the interstitial
space and be drained by the lymphatic vessels toward the lymph
nodes (Chackerian et al., 2002). Once it reaches the lymph nodes,
Mtb infects the local macrophages, thereby initiating lymph node
infection; and the dendritic cells (DCs), which start the process of
epitope presentation and specific Th1-lymphocyte proliferation
(Vilaplana et al., 2014).
Specific lymphocytes are triggered to a broad spectrum of
epitopes, mainly those secreted by replicating Mtb (R-Mtb;
Andersen, 1997; Figure 4), and are attracted to the granuloma to
activate the infected AMs. Meanwhile, DCs are produced in the
granuloma to provide feedback to the lymph node on the need
for more lymphocytes at the infected site (Harding et al., 2015).
LTBI: A Constant Reinfection Process
The AM activation by Th1 lymphocytes causes Mtb destruction,
but also generates NR-Mtb, which are mainly immersed in the
intragranulomatous necrosis generated by the bacilli and the
inflammatory response. These cellular debris together with the
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FIGURE 1 | Anthropomorphic view of the alveoli and the scenario in the lung. The lung is like a big city (i.e., Barcelona) of around 625 km2, filled with 250
million of 25m2 rooms (A,B). Each room contains a cleaner—the alveolar macrophage (C)—that removes every particle that enters with the air every 6 s. Finally,
however, this cleaner becomes filled with lipid inclusions, forms a foamy macrophage, becomes useless and is finally drained out of the room (D).
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FIGURE 2 | Anatomical approach to the alveoli. (A) Shows the main
actors in the alveoli, namely the alveolar macrophage (the cleaner), the type II
pneumocytes (the gardener) that form the surfactant, the epithelial cells that
limit the space and the endothelial cells that limit the capillary net.
Arterial vessels are shown in red, venous vessels in blue and lymphatic vessels in
(Continued)
FIGURE 2 | Continued
green. Fibroblasts produce the collagen fibers that structure the space. (B)
Shows the organization of the alveoli in the alveolar sacs and acinus, and (C)
provides a lower view showing the acinus in the context of the secondary lobe,
surrounded by the interlobular septae net connected to the visceral pleura
(modified from Webb, 2004).
NR-Mtb are phagocytosed by old activated AMs that then
become foamy macrophages (FMs; Cáceres et al., 2009; Russell
et al., 2009), which are finally drained toward the bronchial
escalator. FMs can be destroyed in this drainage, and the NR-Mtb
have the chance to form part of the aerosols induced in the
bronchioles, thereby again infecting the parenchyma. However,
the majority are drained toward the upper portions of the tree,
the pharynx, and are then swallowed into the gastrointestinal
tract (Cardona, 2009). This is a very efficient way to control Mtb
infection, with the immune response only being focused against
R-Mtb; whereas NR-Mtb, which are more resistant to the stress
(Dutta and Karakousis, 2014), are simply drained away. As the
alveolar spaces are smaller in the murine lung, FM get trapped
and are easy to see at the periphery of the granuloma (Cardona
et al., 2003; Cáceres et al., 2009). This dynamic paints a scenario
in which both R-Mtb and NR-Mtb can be found in the same lung,
as described before (Muñoz-Elías et al., 2005). This is possible
because of the presence of Mtb resuscitation-promoting factors
that allow NR-Mtb to revert to R-Mtb (Mukamolova et al., 1998).
Coming back to Figure 4, upon reinfection the immune
response is increasingly directed toward the antigens secreted
by R-Mtb, a process that helps the survival of NR-Mtb, as they
remain hidden from immune surveillance (Andersen, 1997).
Interestingly, a majority of Mtb strains are able to trigger a
Th1 response and to provide a protective immune response, as
good as that induced by BCG (Mollenkopf et al., 2004); although
some exceptions have been reported (Manca et al., 2016). It is
expected that the reinfection process is a common feature in high
incidence countries. This means that there is a constant boost
of the immune response against R-Mtb, which explains why the
usefulness of prophylactic vaccines, such as the Bacillus Calmette
Guerin–BCG-, in these countries is mainly reduced to providing
an advantage to the host when faced with its very first Mtb
challenge, i.e., in neonates. Specifically, it reduces the onset of the
immune response by about 5 days (Jung et al., 2005; Cardona and
Vilaplana, 2014), but does not prevent the infection itself.
LTBI: The Role of the Local Milieu
It is interesting to note that the lesion caused is usually
based on the presence of AMs, some rafts of PMNs, some
intragranulomatous necrosis, and is surrounded by lymphocytes
(the “doughnut” appearance). This is because granulomas, where
the majority of AMs are activated, tend to inactivate the
entry of new lymphocytes. This phenomenon has been well-
described in mice and guinea pigs and appears to arise as a
consequence of different mechanisms, including the competition
to obtain arginine, direct suppression, or apoptosis, amongst
others (Zhang and McMurray, 1998; Ríos-Barrera et al., 2006;
Jeevan et al., 2007).
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FIGURE 3 | Life cycle of Mycobacterium tuberculosis in the lungs according to the dynamic hypothesis. After transmission via aerosol, M. tuberculosis
settles in the alveoli. (II) M. tuberculosis grows inside alveolar macrophages (AM), causing their necrosis. These cells cause a weak, if any, inflammatory response and
the bacilli released are simply phagocytosed by neighboring AMs, causing no lesion. This “unicellular” phase (I) allows the bacilli complete freedom to constantly
generate new infectious foci, even in those hosts that have optimal cellular immune responses. This is because of the lack of antibodies in the alveoli to inactivate the
bacilli and the fact that infected AM do not induce a sufficient inflammatory response to be detected by specific lymphocytes. Once the inflammatory response is
sufficiently intense due to the large number of neighboring infected AMs, the alveoli break their sealed nature, thus allowing the entry of cells from the capillary net and
the drainage of the bacilli toward the lymphatic vessels and regional lymph nodes, where antigenic presentation and lymphocytic proliferation take place (II). These
lymphocytes are attracted to the inflammatory foci, where they activate the infected AM and destroy the bulk of the bacilli (around 90%); the survivors become
non-replicating (NR-Mtb) and rest inside activated AMs or necrotic tissue (III). Once bacillary growth has been controlled, the “cleaning” phase starts. This phase is
characterized by phagocytosis of the necrotic debris by the activated AMs, which retain even more NR-Mtb and become “foamy” by accumulating cellular debris (IV).
These foamy macrophages are then progressively drained with the alveolar fluid toward the bronchi, where they are destroyed. The bacilli contained therein can pass
into internal aerosols (V) and are able to reinfect tissue (VI), although they are mainly drained toward the intestinal tract (VI). This cycle can be interrupted by
encapsulation, which isolates the granuloma. This process occurs as a result of the interlobular septae, which contain fibroblasts that are very sensitive to the
mechanical changes caused by intraparenchymal lesions (IVb). Some hosts can develop an intense neutrophilic response, which is the origin of cavitated lesions (IVc).
Version from Vilaplana and Cardona (2014).
The lung parenchyma in large mammals is structured into 2i
lobes that build a network of interlobular septae which connects
the whole parenchyma with the visceral pleura and transmits the
mechanical force induced by the diaphragm to expand it (Webb,
2004; Figure 2). This network allows the alveolar walls to be as
thin as possible to facilitate gas exchange (Peake and Pinkerton,
2015), as they do not have to transmit the strength of the whole
lung expansion. This fact is very relevant in big mammals as they
have a larger lung parenchyma to expand (Peake and Pinkerton,
2015). These interlobular septae are very sensitive to anyminimal
mechanical change, such as the minimal lesions induced in LTBI
(with a diameter of around 0.5mm), and are able to encapsulate
and isolate them from the healthy parenchyma within about 10
days (Gil et al., 2010). This mechanism is very important as
it helps to stop the drainage of NR-Mtb and finally kills them
as a result of a poly-stress mechanism based on hypoxia, high
pH, starvation, and finally by the hyperosmosis caused by the
accumulation of calcium (Gil et al., 2010).
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FIGURE 4 | Host response repertoire against Mtb infection. The picture
illustrates how, at the onset of infection, a wide-ranging cellular response is
induced against a large epitope repertoire that mainly includes secreted
antigens but also structural ones (A). Once the acute phase is controlled and
there is a majority of non-replicating Mtb (NR-Mtb; Muñoz-Elías et al., 2005),
the immune response decreases while maintaining the memory status (B).
Once reinfection occurs, the immune response is triggered but essentially only
against secreted antigens (C). Modified from Andersen (1997).
Why Does Active TB Occur? Anatomy of
the Lung and Quality of the Lesions for a
Perfect Storm
Looking at the consequences of LTBI, it is clear that it causes
a negligible health impact. Problems arise, however, when the
lesions are not well-controlled and become bigger, thereby
progressively hampering patient health as a result of destruction
of the parenchyma. The main challenge is to understand the
mechanism that allows a tiny lesion of less than 1mm, in the case
of LTBI, to become a lesion with a diameter of around 10mm
(which is the minimum required for detection in a chest X-ray;
Andreu et al., 2004).
Considering the dynamics of Mtb, it is hard to believe in the
concept that a bacillus from an old lesion resuscitates and is able
to trigger a massive infiltration that leads to liquefaction of the
tissue and extracellular growth of the bacilli, which is the current
dogma (Grosset, 2003). In fact, there is considerable experimental
evidence that R-Mtb must constantly attempt to resettle in the
parenchyma to induce new lesions otherwise its fate is to be
drained as illustrated in Figure 3 (Cardona and Ivanyi, 2011).
Recently, an explanation has been provided by the study of
a murine mode of TB in the mouse strain C3HeB/FeJ, which
develops human-like lesions (Marzo et al., 2014). This model
supports the idea that the tiny lesions of LTBI have only a narrow
window of opportunity to generate large lesions, otherwise they
are quickly encapsulated and become unable to do so. Essentially,
this opportunity comes as a result of two factors (Figure 5). The
first of these is infiltration by PMNs, which generate Neutrophilic
Extracellular Traps (NETs) to stop Mtb replication (Ramos-
Kichik et al., 2009). However, this induces the opposite effect as
NETs becomes a platform that allows extracellular growth ofMtb.
This is very interesting because extracellular growth was usually
linked to the presence of liquefaction (Grosset, 2003) and was not
thought to occur before. As such, the presence of NETs helps
rapid enlargement of the lesion. In fact, the relation between
granulocyte accumulation and TB progression was described
before in TB-highly-susceptible (Lyadova et al., 2010) and in
several KO immunosuppressedmice (Gil et al., 2006). The crucial
role of this extracellular bacillary population at the beginning
of the transition from infection to active TB is that opens up
the possibility for an antibody-based therapeutic vaccine that
would help the clearance of this population and stop progression
toward active TB. Indeed, passive antibody therapy has provided
excellent results as regards controlling the evolution of lesions in
an experimental model with SCID mice, which have an impaired
B- and T-cell response and build the response against Mtb with
NK cells and PMNs (Guirado et al., 2006).
The second factor is the coalescence of different yet closely
related lesions, including new ones, as a consequence of local
drainage (Prats et al., 2016). Both these factors mean that 10mm
lesions can be induced in about 10 days (Marzo et al., 2014;
Vilaplana and Cardona, 2014).
Curiously, this phenomenon follows the same physical
processes as soap bubble formation, thus allowing an “in silico”
model, known as the “bubble model” (Prats et al., 2016), to be
developed to help to understand the induction of active TB.
In humans, TB lesions tend to accumulate in the upper lobe
(Dock, 1954). The most favored hypothesis relates this tropism
with the higher oxygen pressure in this region that might favor
Mtb growth. This is related to the gravitational force that causes
the lung to hang from the upper side of the costal thorax, thereby
favoring a higher intraalveolar pressure that reduces capillary
circulation and gas exchange and resulting in a higher partial
higher oxygen pressure.
The mechanical force required to inflate the lungs is generated
by the diaphragm at the base of the lung, which moves
the parenchyma toward the abdominal cavity (Figure 6), thus
resulting in a low breathing amplitude in the upper lobes that also
favors hyperoxia (Gurney, 1991; Guo et al., 2011). Furthermore,
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FIGURE 5 | Evolution of the infection toward active disease. An excess of Th17 allows massive infiltration of the lesions by PMNs. This causes a rapid growth in
their size and the induction of secondary lesions (daughter lesions). Finally, these lesions coalesce, which results in the evolution of small granulomas (<1mm) to large
infiltrations that can liquefact and cavitate, thus exceeding the ability of the interlobular septae to encapsulate them. Time period from (A–D), days 21, 28, 30 and 33
respectively.
it also causes a lack of local particle drainage in the upper lobes
and, therefore, an increase in the bacillary load faced by the AM
(Figure 6). This favors a response similar to that triggered against
extracellular bacilli, firstly stimulating PMN infiltration (Gil et al.,
2006; Gan et al., 2008) and then an immune response dominated
by the Th17 response, which also favors infiltration with PMNs
(Korn et al., 2009; Torrado and Cooper, 2010). An “in silico”
model has recently been built to illustrate this process (Cardona
and Prats, 2016).
Two main lesions can be detected in pulmonary TB in
humans: small, proliferative lesions that harbor a low bacillary
load and mainly comprise epithelioid cells and are well-
structured and fibrous, and exudative lesions, in which PMN
infiltration is the major component and pus (liquefaction) may
also be present (Figure 7; Prats et al., 2016). The evolution of TB
results in a kind of patchwork scenario, comprising proliferative
and exudative lesions, that is dependent on local endobronchial
dissemination (Medlar, 1955). Other factors, such as a certain
genetic tendency of AMs to trigger a stronger inflammatory
response against Mtb or to induce more or less apoptosis,
may also play a role, although which particular factor might
have an influence has not been elucidated to date (Abel et al.,
2014).
There is also extrapulmonary TB, which can be linked to
immunosuppression in the case of meningeal or miliary forms,
even though Mtb is able to infect any tissue. Extrapulmonary TB
requires the entry of Mtb in the bloodstream (Krishnan et al.,
2010). Although, some authors have claimed this to be due to
the ability of Mtb to enter into epithelial cells and blood vessels,
classically this has been linked to local disruption of the aberrant
capillary net built around Mtb granulomas (Hunder, 1996); with
larger lesions leading to a higher risk of dissemination (Medlar,
1955).
In summary, infection with Mtb clearly follows the “damage
theory” paradigm (Casadevall and Pirofski, 1999; Cardona, 2010)
in which both pathogen type and type of host’ response triggered
against the pathogen are key to induction of the disease.
THERAPEUTIC VACCINES
The use of “therapeutic vaccines” is an old strategy designed by
Robert Koch himself (Cardona, 2006a) and received significant
attention until the onset of chemotherapy. The fascinating story
of the large-scale therapeutic used of the so called “tuberculins”
has recently been reviewed by Vilaplana and Cardona (2010).
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FIGURE 6 | Importance of breathing amplitude in the lung, for the
induction of active TB. In mammals, breathing in, or inhaling, occurs due to
the contraction and flattening of the diaphragm, a domed muscle that
separates the thorax and abdomen (A). This action increases the space of the
alveoli, although not homogeneously. The lobes of the base experience the
largest amplitude, whereas the upper lobes experience almost no movement.
This fact has a major consequence, namely a very important drainage of bacilli
after destruction of the alveolar macrophage (AM) toward neighboring alveoli in
the base, with almost none at the upper lobes. This means that new AMs face
a lower bacillary load in the base than in the upper lobes (B). The increase of
the bacillary load stimulates necrosis and neutrophilic infiltration (C). This
hypothesis can explain why the evolution toward active TB mainly occurs in
the upper lobes.
Figure 8 shows a scenario in which a therapeutic vaccine can
work together with chemotherapy. In essence, we expect the
same phenomenon against latent and in active TB, with the
therapeutic vaccine being used once there is a predominance
of NR-Mtb and chemotherapy only being given to maintain
sufficient tissue concentrations to stop regrowth of the bacilli.
This is the moment to use a therapeutic vaccine, in order to
achieve an extra bactericidal activity.
Two mechanisms of action can be defined. The first of these,
which we can refer to as “bacilli-directed therapy,” increases the
surveillance capacity against NR-Mtb by enhancing the cellular
immunity to find those antigens linked to NR-Mtb that are
hidden to the immune surveillance (Figure 4). In the case of the
second, which is known as “host-directed therapy,” the objective
is to modulate the inflammatory response in order to avoid
extracellular growth of the bacilli fuelled by the accumulation of
neutrophiles, or the Th2 response (or “Koch phenomenon”), that
induce intragranulomatous necrosis.
Bacilli-Directed Therapy: Focusing on
Killing the Bacilli
Mycobacterium w (Mw), Also Known As
Mycobacterium indicus pranii (MIP)
This strain is in the Mycobacterium avium complex (Alexander
and Turenne, 2015) and was used heat-killed in initial
attempts to develop a therapeutic indication in patients with
borderline lepromatous or lepromatous leprosy to invigorate cell-
mediated immunity. Patients receiving it exhibited rapid clinical
improvement and improved histopathology of skin lesions, and it
was found to significantly reduce the bacillary load (Talwar et al.,
1990; Zaheer et al., 1993; Narang et al., 2005). Large quantities of
data were obtained during clinical trials in India involving 80,000
patients receiving a treatment that combined chemotherapy with
the administration of heat-killedMw every 3 months.
In Mtb infection, the mechanism of action is based on the
induction of a Th1 response and a reduction of Tregs (Das
et al., 2015). This has been demonstrated in an experimental
model in C57Bl/6 mice, with a significant decrease in bacillary
load being achieved upon combining chemotherapy for 60
days with Mw vaccination every 2 weeks, with a total of five
inoculations (Rawat et al., 2013). In addition, a combination of
chemotherapy plus Mw also induced a reduction in bacillary
load in an experimental guinea pig TB model (Rawat et al.,
2013). In this case, the protective effect was related to an increase
in CXCL10 and CXCL11 chemokines. Adjunctive therapy with
Mw has been shown to be effective against multidrug resistant
strains and has demonstrated its ability to stop extrapulmonar
dissemination (Faujdar et al., 2011). More recently, in a trial
involving 1400 patients with TB pericarditis (Mayosi et al.,
2014) the administration of five injections of Mw over 3
months as an adjuvant to chemotherapy had no significant
effect on the incidence of death, cardiac tamponade requiring
pericardiocentesis, or constrictive pericarditis.
RUTI
RUTI was the first therapeutic vaccine designed with the aim
of killing NR-Mtb. This vaccine comprised fragments of Mtb
cultured under stress conditions and the idea arose upon
visualizing the drainage of NR-Mtb from the granulomas inside
FMs (Cardona, 2006b). The aim was to induce an immune
response that would be able to survey NR-Mtb. As we have
noted previously, the immune response is mainly focused against
R-Mtb antigens, therefore the question was how to change this.
Firstly, this would require a short antibiotic treatment to kill
the R-Mtb (Figure 9). This chemotherapy treatment would also
be responsible for stopping lymphocytic proliferation and would
start to disintegrate the granuloma and allow the entry of new,
inactivated AMs or monocytes, thus making the granuloma a
suitable site for further entry of a new repertoire of lymphocytes
without the risk of being suppressed. It would also reduce the
bacillary load to a minimum and would reduce the risk of
the toxic “Koch phenomenon,” which was known to be the
origin of the intragranulomatous necrosis (Gil et al., 2006).
This risk can also be minimized by removing the majority of
lipoarabinomannan (LAM) from the Mtb fragments. Due to
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FIGURE 7 | Lesion spectrum of Mtb infection. Histological evolution after Mtb infection. Initial foci containing a mixture of neutrophils, macrophages and
lymphocytes (A) are soon controlled by the encapsulation process and either calcify (B) or progress with constant reactivation of the bacillary load in foamy
macrophages of the neighborhood. This is typical in the murine infection (C). These lesions could fall into the category of proliferative lesions. Exudative lesions are
characterized by the large-scale infiltration of neutrophils, a high bacillary burden, and the presence of massive necrosis (D).
its endotoxin-like nature, LAM was shown to be responsible
for promoting intragranulomatous necrosis as a result of a
“Schwartzman reaction,” which was linked to the origin of the
“Koch phenomenon” (Cardona et al., 2001).
The criterion for the protective mechanism expected from
RUTI (the GO/No-GO criteria) was to demonstrate the
triggering of a broad response against R-Mtb and NR-Mtb
antigens, and this was found to be the case. Once its bactericidal
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FIGURE 8 | Therapeutic vaccination as coadjuvant for chemotherapy. This is a theoretical approach to the dynamics of the bacillary concentration during
chemotherapy and the influence of vaccination as a coadjuvant. Initially, the early bactericidal activity induces a massive reduction in the bacillary load by killing
replicating bacilli (R-Mtb). Subsequently, non-replicating bacilli (NR-Mtb) dominate and are the responsible for the reinfection process and the appearance of R-Mtb
during chemotherapy (Muñoz-Elías et al., 2005; Cardona, 2006b). The purple dotted line shows a proposal of the time-point to introduce the therapeutic vaccination,
once a drastic reduction of the bacillary load is obtained and the NR-Mtb becomes the majority population. From there, the evolution of R-Mtb (green) and NR-Mtb
(red) is also drawn in dotted lines to show the added bactericidal effect. Panel (A) shows the treatment of LTBI with isoniazid. Panels (B,C) shows the treatment of
active TB, considering one of the worse cases (i.e., with a bacillary load of 9 logs), in sensitive and multidrug resistant (MDR) TB, respectively. In both cases the gray
box shows the initial intensive phase period of chemotherapy.
activity when administered after chemotherapy in murine and
guinea pig models had been demonstrated (Cardona, 2006b),
RUTI showed an ability to generate this polyantigenic response
in 16 healthy volunteers (Vilaplana et al., 2010), and in HIV-
positive and -negative patients with LTBI (Nell et al., 2014)
after INH treatment for 1 month, in a phase II clinical trial
(with 98 patients). In this case, a definitive dose was chosen
to be more effective (25 µg) and only one shot was required
to induce the desired response. Only local adverse events
were detected. These were mainly non-severe, with a delayed
presence of local self-resolved painless nodulation at 3 weeks
post-vaccination on average. Abscessification was only detected
in four cases. The frequency and severity of these adverse
events were correlated with HIV-positive subjects, high vaccine
dose and were more frequent after the second administration
of the vaccine. After this trial, the RUTI production process
changed to include a filtration step in an effort to reduce
the nodulation at the inoculation site (Kaufmann et al.,
2014).
H56
This is the proposal from the Statens Serum Institute and uses
a fusion protein containing epitopes of ESAT-6 and Ag85B
antigens, which are immunodominant in the secreted proteins of
R-Mtb, plus the antigen Rv2660c, which is related to the NR-Mtb.
This vaccine demonstrated a consistent bactericidal effect in
the Cornell-like model in mice, which combines chemotherapy
once the chronic phase of the infection has been established in
the C57BL/6 strain, with two or three inoculations of this vaccine
(Aagaard et al., 2011). It shows a similar protection as the RUTI
vaccine (Cardona et al., 2005) and also demonstrated its ability to
protect against the progression from LTBI to active TB induced
by the administration of anti-TNF antibodies, in an experimental
model in cynomolgus macaques (Lin et al., 2012). Recently
published data from the phase I clinical trial published recently
show a strong Th1 response with a strong central memory
phenotype in the 25 subjects enrolled. No serious adverse events
were reported, although nine subjects (36%) presented transient
cardiovascular adverse events (Luabeya et al., 2015).
Host-Directed-Therapy: Modulating the
Host Reaction
Heat-Killed M. vaccae/M. obuense
The idea of using heat-killed Mycobacterium vaccae came from
the observation that some people from villages in Uganda where
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FIGURE 9 | Therapeutic approach of the RUTI vaccine. This figure shows the natural evolution of the infection, with constant cycles of reinfection (A,D,G). During
chemotherapy there is a reduction of the lesion and the cellular immune response (B,E,H). Upon vaccination with RUTI (C,F,I) there is an increase in the immune
response that includes a wider repertoire, compared to that obtained with the usual reinfection process, which is more focused on the secreted antigens, as shown in
Figure 4.
this species was abundant in the dust had some degree of natural
protection against TB. The other pointer was the interference of
environmental mycobacteria (EM) with the protection elicited
by BCG. This issue was first addressed experimentally in mice
by Brown et al. (1985), who added M. vaccae to drinking water
for different periods of time before administering BCG. Upon
testing the splenocytes for their proliferation capacity when
stimulated with killed mycobacteria, oral administration was
found to either enhance, mask or interfere with the protective
effect of BCG. Meanwhile, two types of cellular responses against
infections caused by intracellular pathogens were identified. The
“Listeria-like” one, which is able to induce a cellular response
without causing intragranulomatous necrosis, and the “TB-like”
or “Koch phenomenon,” which is responsible for inducing this
necrosis (Rook et al., 1981; Stanford, 1991). This response was
linked to a predominance of Th1 or Th2 responses, respectively.
In light of these findings, efforts were focused on the more
controlled administration using parental immunization of heat-
killedM. vaccae to convert the existing necrotizing response into
a protective one (i.e., from Th2 to Th1; Stanford, 1991). This
approach was first used to treat leprosy patients, and shortly
thereafter was used in TB patients in several trials that have
recently been summarized in the literature, showing no definitive
results (Gröschel et al., 2014). Along similar lines, von Reyn’s
group had a positive experience in the DARDAR clinical trial
in Tanzania, where the combination of several inoculations with
heat-killed M. vaccae reduced TB definite cases by 39% in
HIV-positive patients (von Reyn et al., 2010). Further genomic
characterization has shown that theM. vaccae strain used by this
group was actually M. obuense rather than M. vaccae (Lalvani
et al., 2013). In 2011, a high yield and scalable GMP broth
manufacturing process was developed in collaboration with
Aeras. The vaccine (now DAR-901) is in Phase I since 2014, as is
intended to be a booster vaccine for the prevention of TB in both
HIV-infected and HIV-uninfected adolescents and adults primed
by childhood BCG immunization (Kaufmann et al., 2014).
Heat-Killed M. manresensis
This approach was developed after the observation of the key
role of the Th17 response in the induction of active TB (Marzo
et al., 2014). As Th17 lymphocytes and Tregs are in constant
balance, this led to the idea of increasing Tregs in order to
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reduce the presence of Th17 lymphocytes. This could be done
by inducing tolerance using the oral administration of low dose
heat-killed mycobacteria. The role of regulatory T cells (Tregs)
in TB has been controversial as they were initially thought to
fuel progression toward active TB (Semple et al., 2013). However,
recent reports seem not to support this idea (Green et al., 2010;
Leepiyasakulchai et al., 2012), thus leading to a more neutral role
in their interference against the Th1 response, and showing its
protection against the development of active TB lesions.
Oral administration of heat-killed Mtb and BCG every day
or 2 days was shown to delay the induction of active TB in
a murine model in C3HeB/FeJ mice, in which “human-like”
lesions can be reproduced (Cardona, 2015). This led to the search
for an environmental mycobacterium in order to produce an
affordable industrial product. As a result, the fortuitum complex
was selected. As this bacillus is commonly found in drinking
water, it can be classified as food supplement in regulatory terms.
The strain used was obtained from a natural source (the river
Cardener, which flows through the city of Manresa, Catalonia).
Once the genome had been sequenced to satisfy regulatory
requirements, it was realized that the strain was quite close
to Mycobacterium setense but exhibited sufficient taxonomical
differences to be considered a new species. As such, it was named
Mycobacterium manresensis after the city of Manresa (Rech et al.,
2015).
Experimental data show that the oral administration of heat-
killed M. manresensis is able to induce memory-specific Tregs
and to delay the exaggerated inflammatory response that leads
to the induction of active TB (Cardona et al., 2016). It has
been speculated that this delay might provide sufficient time
for the fibroblasts in the interlobular septae present in human
lungs to encapsulate the lesions (Figure 10). The first clinical
trial has demonstrated that daily administration of 105 heat-
killedM. manresensis (Nyaditum resae R©, Manremyc sl, Manresa,
Catalonia) for 14 days induces memory PPD specific Tregs, and
has an excellent tolerability (Montane et al., 2014).
Other Therapeutic Vaccines
Other promising candidates are still in the preclinical phase.
Several DNA vaccines codifying mainly for the hsp65, Ag85A,
and B antigens have been tested. Some of these have
demonstrated their value in murine models, with or without
chemotherapy and with a wide range of protection, as reviewed
by Lowrie (2006). Recently, a group of therapeutic vaccines
comprising different combinations of fusion proteins has
provided very promising results. Thus, the “3-iron”vaccine
candidate, which includes several iron-acquisition proteins
(Shanley et al., 2014), has demonstrated a reduction in pathology
and increased survival in the guinea pig model without the
help of chemotherapy, although it was unable to reduce
the bacillary load in the lung. Interestingly, this candidate
showed this protection against highly virulent MDR strains.
Similarly, ID93/GLA-SE, a candidate designed by the Reed
group (Coler et al., 2013), is a combination of M. tuberculosis
proteins associated with virulence (Rv2608, Rv3619, and
Rv3620) or latency (Rv1813). ID93/GLA-SE has demonstrated its
therapeutic value in combination with rifampicin and isoniazid
in SWR/J mice and cynomolgus monkeys. This candidate
elicits a robust Th1 response and is able to reduce the
pulmonary bacillary load and increase the survival of the
animals.
CONCLUSION
Infection withMtb clearly follows the “damage theory” paradigm
in which interaction with the host is paramount for the induction
of active disease. The fact that Mtb is able to grow inside the AM
is clearly one advantage, but not the only one, as other pathogens
are also able to do this. However, it is also able to induce necrosis
inside these lesions. This favors additional growth of the bacilli
and helps the progressive destruction of the parenchyma that
leads to the induction of active TB.
FIGURE 10 | Therapeutic approach of Mycobacterium manresensis. This picture illustrates how administration of M. manresensis increases the Treg response
and results in a decrease in the Th17 response (B). This stops the neutrophilic infiltration of the lesions, and stops their growth, and it has been speculated that this
might provide sufficient time for them to become encapsulated (A). This might avoid the progression toward coalescence, liquefaction, and cavitation.
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TABLE 1 | Therapeutic vaccines against tuberculosis in clinical phase.
Vaccine Mode of action Mechanism of action Antigens References
MIP Bacilli-directed therapy Th1 response M. avium complex heat-killed whole bacilli Das et al., 2015
RUTI Th1 polyantigenic response M. tuberculosis fragments Nell et al., 2014
H56 Th1 response ESAT-6; CFP-10; Rv2660c Luabeya et al., 2015
M. vaccae/obuense Host-directed therapy Th1 response Heat-killed whole bacilli Lalvani et al., 2013
M. manresensis Treg response Montane et al., 2014
Prevention of the infection itself seems to be controlled
by some intrinsic mycobactericidal properties of the AM and,
possibly, the properties of the surfactant. The immune response is
not able to avoid reinfection because of the difficulty of attracting
specific lymphocytes to isolated infected AMs and the lack of
antibodies in the alveoli. Similarly, the induction of NR-Mtb once
the immune response has been triggered makes very difficult to
develop a chemotherapy that is able to eradicate them from the
tissues in a short-period of time.
As such, there is an urgent need for therapeutic vaccines
in the fight against TB, especially for those persons with
LTBI. The current approach (6–9 months INH treatment) is
very difficult to follow up for two reasons. Firstly, because of
problems with compliance and toxicity, and secondly because
reinfection is highly probable in high incidence countries once
the treatment has finished, thus making this effort worthless.
Equally, the presence of INH-resistant strains could potentially
make this treatment highly ineffective. Although other shorter
treatments are currently being proposed, they can still not
be compared with an immunological intervention in terms of
compliance.
Therapy for the disease itself is also of great importance,
and in this regard, it would be highly significant to find an
immunological approach to shorten treatment itself and to avoid
relapse of the disease.
KEY POINTS
1. The anti-infection capacity of the alveoli is very much
conditioned by their main function: the gas exchange.
2. Mtb infects alveolar macrophages, cells with a dedicated
cleaning task that do not elicit an inflammatory response
which could alter their minimal architecture. The price of this,
however, is to hamper antigen presentation and attraction of
the cellular immune response.
3. Alveoli maintain a strong air-tightness to keep the appropriate
surface tension, thus avoiding their collapse and allowing
breathing mechanics. However, this prevents the entry of
plasma and means no antibodies are present.
4. Mtb reinfection is always possible. Infection by itself, however,
does not affect the health status of an individual.
5. The induction of active TB is caused by an exaggerated
inflammatory response against the bacilli. This has been
explained as being induced by a high Th2 response and, more
recently, by a strong neutrophilic reaction mediated by a Th17
response.
6. Therapeutic vaccines focused on bacilli-directed therapy are
usually used as chemotherapy adjuvants and increase the Th1
response (Table 1).
7. Therapeutic vaccines focused on host-directed therapy can
also be administered independently of chemotherapy and
raise either a Th1 or a Treg response (Table 1).
8. All therapeutic vaccines can be given in different steps
against Mtb infection, and have the advantage of not being
conditioned by the drug sensitivity profile of Mtb.
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